GO:1903063 negative regulation of reverse cholesterol transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903063 describes any process that stops, prevents, or reduces the frequency, rate, or extent of reverse cholesterol transport (RCT), the pathway that moves excess cholesterol from peripheral tissues back to the liver for excretion.
• RCT is a multi-step process involving HDL biogenesis, cholesterol efflux from macrophages, HDL remodeling, and hepatic uptake and biliary excretion; negative regulation can act at any of these steps.
• Key molecular players whose inhibition suppresses RCT include LXR, PPARgamma, ABCA1, ABCG1, SR-BI, and hepatic lipase/endothelial lipase.
• Liver-specific LXR inhibition represses RCT in cholesterol-fed mice, demonstrating that nuclear receptor signaling is a central control point for this negative regulation.
• MEK1/2 inhibitors activate macrophage ABCG1 expression and stimulate RCT, showing that ERK1/2 signaling normally restrains this pathway.
• Dysregulation of RCT is linked to atherosclerosis, obesity, and hepatic cholesterol accumulation, making GO:1903063 a target-rich area for cardiovascular and metabolic research.
Description
Reverse cholesterol transport (RCT) is the physiological process by which excess cholesterol is removed from peripheral cells, including macrophages in the arterial wall, and transported to the liver for excretion into bile. This pathway is central to cholesterol homeostasis and protects against atherosclerotic cardiovascular disease. GO:1903063, negative regulation of reverse cholesterol transport, refers to any process that stops, prevents, or reduces the frequency, rate, or extent of RCT. Understanding this negative regulation is critical because suppressing RCT can promote cholesterol accumulation in tissues and accelerate atherosclerosis. At the molecular level, RCT is orchestrated by HDL particles, cholesterol transporters such as ABCA1 and ABCG1, nuclear receptors such as LXR and PPARgamma, and hepatic uptake receptors including SR-BI. Negative regulation of RCT can occur through inhibition of these components, for example by suppressing LXR activity, reducing ABCA1/ABCG1 expression, or altering HDL remodeling enzymes. In cholesterol-fed mice, liver-specific LXR inhibition represses RCT, directly demonstrating negative regulation of this pathway. For researchers, GO:1903063 provides a framework to study how genetic, pharmacological, or environmental perturbations reduce RCT and contribute to disease. This article integrates the QuickGO definition with published literature to outline the mechanisms, key genes, disease links, and experimental models relevant to negative regulation of reverse cholesterol transport.
negative regulation of reverse cholesterol transport At A Glance
| GO ID | GO:1903063 |
|---|---|
| GO term | negative regulation of reverse cholesterol transport |
| Ontology | biological_process |
| Synonym | down regulation of reverse cholesterol transport; down-regulation of reverse cholesterol transport; downregulation of reverse cholesterol transport; inhibition of reverse cholesterol transport |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of reverse cholesterol transport |
| Related process | Reverse cholesterol transport (RCT), cholesterol efflux, HDL metabolism |
| Key regulators | LXR, PPARgamma, ABCA1, ABCG1, SR-BI, hepatic lipase, endothelial lipase |
| Disease relevance | Atherosclerosis, obesity, hepatic cholesterol accumulation |
What Is GO:1903063?
GO:1903063 (negative regulation of reverse cholesterol transport) is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of reverse cholesterol transport. In other words, it encompasses molecular and cellular events that inhibit the movement of cholesterol from peripheral tissues back to the liver for excretion. This includes downregulation of cholesterol efflux transporters, suppression of nuclear receptor signaling that drives RCT, and inhibition of hepatic cholesterol uptake or biliary secretion.
Why Is negative regulation of reverse cholesterol transport Important in Cell Biology?
Negative regulation of reverse cholesterol transport is important because RCT is a primary defense against cholesterol accumulation in peripheral tissues, and its suppression directly contributes to atherosclerosis and metabolic disease. When RCT is inhibited, excess cholesterol remains in macrophages and other cells, promoting foam cell formation and plaque development. Moreover, conditions such as morbid obesity are associated with decreased expression of RCT-related genes, linking negative regulation of this pathway to human metabolic dysfunction. Understanding the mechanisms that suppress RCT can reveal therapeutic targets for cardiovascular and metabolic diseases.
• Suppression of RCT leads to cholesterol accumulation in macrophages, a hallmark of atherosclerosis.
• Liver-specific LXR inhibition represses RCT in cholesterol-fed mice, showing that nuclear receptor signaling is a key control point.
• MEK1/2 inhibitors activate macrophage ABCG1 and stimulate RCT, indicating that ERK1/2 signaling normally restrains this pathway.
• Hepatic lipase and endothelial lipase modulate HDL-mediated RCT, and their activities can influence negative regulation of this process.
• Morbid obesity is associated with decreased expression of RCT-related genes in peripheral blood mononuclear cells, linking negative regulation to metabolic disease.
• Pharmacological interventions such as QiShenYiQi pill promote RCT via PPARgamma-LXRalpha/beta-ABCA1, highlighting the therapeutic potential of targeting negative regulators.
• Gypenosides lower hepatic cholesterol through multi-omics mechanisms that may involve modulation of RCT-related pathways.
• Cholesterol homeostasis is essential for health, and its disruption via negative regulation of RCT contributes to cardiovascular disease.
• Studying negative regulation of RCT helps identify new drug targets for dyslipidemia and atherosclerosis.
• CRISPR-based models of RCT genes enable causal testing of negative regulators in disease models.
What Happens During negative regulation of reverse cholesterol transport?
Inhibition of cholesterol efflux from macrophages
In simple terms: This step blocks the removal of cholesterol from immune cells in blood vessel walls.
Reverse cholesterol transport begins with cholesterol efflux from peripheral cells, especially macrophages, to lipid-poor apolipoprotein A-I via ABCA1 and to mature HDL via ABCG1. Negative regulation of RCT can occur when these transporters are downregulated or their activity is inhibited. For example, MEK1/2 inhibitors activate macrophage ABCG1 expression and enhance RCT, implying that ERK1/2 signaling normally suppresses ABCG1 and restrains efflux. Thus, inhibition of cholesterol efflux is a primary mechanism of negative regulation of RCT.
Suppression of HDL biogenesis and remodeling
In simple terms: This step reduces the formation and maturation of HDL particles that carry cholesterol to the liver.
HDL biogenesis involves the lipidation of apoA-I by ABCA1, and HDL remodeling is influenced by enzymes such as hepatic lipase and endothelial lipase. Negative regulation of RCT can be achieved by reducing HDL particle number or function. Hepatic lipase and endothelial lipase play roles in HDL-mediated RCT, and their modulation can affect the efficiency of cholesterol transport. When HDL biogenesis or remodeling is impaired, the overall rate of RCT decreases, representing negative regulation of the pathway.
Inhibition of hepatic cholesterol uptake and biliary excretion
In simple terms: This step prevents the liver from taking up cholesterol from HDL and excreting it into bile.
The final steps of RCT involve selective uptake of HDL cholesterol by the liver via SR-BI and subsequent excretion into bile. Negative regulation of RCT can occur through suppression of hepatic SR-BI expression or inhibition of biliary cholesterol secretion. Liver-specific LXR inhibition represses RCT in cholesterol-fed mice, demonstrating that hepatic nuclear receptor signaling is required for efficient RCT and that its inhibition negatively regulates the pathway. Thus, hepatic steps are critical control points for negative regulation of RCT.
Transcriptional repression of RCT genes
In simple terms: This step turns down the genes that make the proteins needed for cholesterol removal.
Nuclear receptors such as LXR and PPARgamma transcriptionally regulate ABCA1, ABCG1, and other RCT genes. Negative regulation of RCT can be mediated by reduced activity or expression of these transcription factors. For instance, liver-specific LXR inhibition represses RCT in mice, and PPARgamma activation promotes RCT via the LXRalpha/beta-ABCA1 pathway, indicating that loss of PPARgamma signaling would negatively regulate RCT. Therefore, transcriptional repression of RCT genes is a key mechanism of negative regulation.
Post-translational and signaling control
In simple terms: This step uses signaling switches to put the brakes on cholesterol removal.
Signaling pathways such as ERK1/2 can modulate RCT by affecting the stability or activity of cholesterol transporters. MEK1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transport, suggesting that ERK1/2 signaling normally suppresses ABCG1 and thus negatively regulates RCT. Additionally, hepatic lipase and endothelial lipase activities are post-translationally regulated and influence HDL metabolism and RCT. These signaling and post-translational mechanisms provide additional layers of negative regulation.
Key Genes Involved in GO:1903063 negative regulation of reverse cholesterol transport
The following genes and proteins are central to reverse cholesterol transport and its negative regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCA1 | Mediates cholesterol efflux to apoA-I, initiating HDL biogenesis | Target for promoting RCT; its downregulation negatively regulates RCT |
| ABCG1 | Mediates cholesterol efflux to mature HDL | ERK1/2 inhibition activates ABCG1 and RCT; its suppression negatively regulates RCT |
| LXR (NR1H3/NR1H2) | Nuclear receptor transcriptionally activating ABCA1, ABCG1, and other RCT genes | Liver-specific LXR inhibition represses RCT in mice |
| PPARgamma | Nuclear receptor promoting RCT via LXRalpha/beta-ABCA1 pathway | Pharmacological activation promotes RCT; its inhibition negatively regulates RCT |
| SR-BI (SCARB1) | Hepatic receptor mediating selective uptake of HDL cholesterol | Key for final steps of RCT; its downregulation negatively regulates RCT |
| Hepatic lipase (LIPC) | Enzyme involved in HDL remodeling and RCT | Modulates HDL-mediated RCT; altered activity affects RCT rate |
| Endothelial lipase (LIPG) | Enzyme that hydrolyzes HDL phospholipids and affects HDL metabolism | Influences HDL-mediated RCT; its activity can negatively regulate RCT |
| ApoA-I (APOA1) | Main apolipoprotein of HDL, acceptor for cholesterol efflux | Essential for HDL biogenesis and RCT; reduced levels negatively regulate RCT |
| ApoE (APOE) | Apolipoprotein involved in cholesterol transport and HDL metabolism | Modulates RCT; its deficiency impairs RCT |
| CETP | Cholesteryl ester transfer protein, transfers cholesteryl esters between lipoproteins | Affects HDL cholesterol levels and RCT efficiency |
| LCAT | Lecithin-cholesterol acyltransferase, esterifies cholesterol on HDL | Promotes HDL maturation and RCT; its reduction negatively regulates RCT |
| ERK1/2 (MAPK3/MAPK1) | Signaling kinases that suppress ABCG1 and RCT | MEK1/2 inhibitors activate RCT; ERK1/2 inhibition is a research tool |
| MEK1/2 (MAP2K1/MAP2K2) | Upstream kinases activating ERK1/2 | Inhibitors activate macrophage ABCG1 and RCT |
| Leptin receptor (LEPR) | Signaling receptor linked to RCT gene expression | Its pathway is decreased in morbid obesity and related to liver function |
| Gypenosides targets | Multi-omics targets lowering hepatic cholesterol | May modulate RCT-related pathways |
| QiShenYiQi targets | Herbal components promoting RCT via PPARgamma-LXRalpha/beta-ABCA1 | Used to study pharmacological promotion of RCT |
How Is negative regulation of reverse cholesterol transport Regulated?
Negative regulation of reverse cholesterol transport is controlled at multiple levels. Transcriptional regulation by nuclear receptors LXR and PPARgamma directly affects ABCA1 and ABCG1 expression, and their inhibition reduces RCT. Signaling through the MEK/ERK pathway suppresses ABCG1 and RCT, as MEK1/2 inhibitors activate both. Post-translational regulation of hepatic lipase and endothelial lipase modulates HDL remodeling and RCT efficiency. Additionally, metabolic states such as morbid obesity are associated with decreased expression of RCT-related genes, indicating systemic regulation.
negative regulation of reverse cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LXR | Atherosclerosis, hepatic cholesterol accumulation | Liver-specific LXR knockout or knock-in mice |
| ABCG1 | Atherosclerosis, macrophage foam cell formation | Macrophage-specific ABCG1 knockout or overexpression |
| PPARgamma | Atherosclerosis, metabolic syndrome | PPARgamma knockout or transgenic mice |
| LEPR | Obesity, metabolic dysfunction | Leptin receptor knockout or overexpression models |
| SR-BI | Atherosclerosis, HDL metabolism | SR-BI knockout or liver-specific transgenic mice |
Atherosclerosis
Negative regulation of reverse cholesterol transport promotes atherosclerosis by reducing cholesterol efflux from macrophages and increasing foam cell formation. Suppression of RCT via LXR inhibition or reduced ABCA1/ABCG1 activity leads to cholesterol accumulation in arterial walls. Therapeutic strategies that promote RCT, such as PPARgamma activation, inhibit atherosclerosis in animal models.
Obesity and metabolic dysfunction
Morbid obesity is associated with decreased expression of genes related to reverse cholesterol transport and leptin receptor pathways in peripheral blood mononuclear cells, and these changes correlate with liver function. This suggests that negative regulation of RCT contributes to metabolic dysfunction in obesity. Targeting RCT pathways may improve metabolic outcomes.
Hepatic cholesterol accumulation
Negative regulation of RCT can lead to hepatic cholesterol accumulation, as shown by multi-omics studies of gypenosides lowering hepatic cholesterol. Liver-specific LXR inhibition represses RCT and may exacerbate hepatic cholesterol burden. Thus, hepatic RCT is critical for whole-body cholesterol homeostasis.
From negative regulation of reverse cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LXR in liver negatively regulate RCT? | Liver-specific LXR knockout mouse |
| Does ERK1/2 inhibition activate ABCG1 and RCT? | Macrophage ERK1/2 knockout or MEK1/2 inhibitor treatment |
| Does PPARgamma activation promote RCT and inhibit atherosclerosis? | PPARgamma agonist treatment in ApoE-/- mice |
| Is ABCA1 required for HDL biogenesis and RCT? | ABCA1 knockout or knock-in mice |
| Does SR-BI downregulation reduce hepatic cholesterol uptake? | Liver-specific SR-BI knockout or overexpression |
| Does leptin receptor signaling affect RCT gene expression? | Leptin receptor knockout or obese mouse models |
How to Study the negative regulation of reverse cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vivo RCT assay | Rate of cholesterol movement from macrophages to feces | Assessing negative regulation of RCT in mice |
| qPCR/RNA-seq | Expression of RCT genes | Detecting downregulation of ABCA1, ABCG1, LXR |
| Cholesterol efflux assay | Efflux from macrophages to apoA-I/HDL | Testing inhibitors of RCT |
| Western blot | Protein levels of ABCG1, ABCA1, ERK1/2 | Evaluating signaling effects on RCT |
| Lipase activity assay | Hepatic lipase and endothelial lipase activity | Studying HDL remodeling in RCT |
| Multi-omics | Transcriptomic and metabolomic changes | Identifying pathways lowering hepatic cholesterol |
| Flow cytometry | HDL binding and uptake | Measuring SR-BI function |
In vivo reverse cholesterol transport assays
RCT can be measured in vivo by injecting radiolabeled cholesterol into macrophages and tracking its appearance in plasma, liver, and feces. This method directly assesses the rate of RCT and the impact of negative regulators. Liver-specific LXR inhibition represses RCT in cholesterol-fed mice, as shown by such assays.
Gene expression analysis
Quantitative PCR and RNA-seq can measure expression of RCT-related genes such as ABCA1, ABCG1, LXR, and PPARgamma in tissues or cells. Decreased expression of these genes indicates negative regulation of RCT. Multi-omics approaches can identify pathways affecting hepatic cholesterol.
Cholesterol efflux assays
Cholesterol efflux from macrophages to apoA-I or HDL can be measured using radiolabeled or fluorescent cholesterol. This assay quantifies the first step of RCT and can detect negative regulation by signaling inhibitors. MEK1/2 inhibitors increase efflux via ABCG1.
Protein and signaling analysis
Western blotting and kinase activity assays can assess ERK1/2 phosphorylation and ABCG1 protein levels. Hepatic lipase and endothelial lipase activities can be measured enzymatically. These methods reveal post-translational mechanisms of negative regulation.
How CRISPR Can Be Used to Study GO:1903063 negative regulation of reverse cholesterol transport
Knockout
CRISPR knockout of RCT genes such as ABCA1, ABCG1, LXR, or SR-BI can model negative regulation of reverse cholesterol transport by eliminating their function. For example, liver-specific LXR knockout represses RCT in mice. Macrophage ABCG1 knockout reduces cholesterol efflux, mimicking negative regulation.
Point Mutation
CRISPR point mutation can introduce loss-of-function or gain-of-function mutations in RCT genes to study their impact on negative regulation. For instance, mutating phosphorylation sites in ABCG1 or ERK1/2 could reveal regulatory mechanisms. Point mutations in ABCA1 can impair cholesterol efflux and negatively regulate RCT.
Knock-in
CRISPR knock-in can insert reporter tags or human disease variants into RCT genes to track their expression and function. For example, knocking in a luciferase reporter into the ABCA1 locus allows monitoring of transcriptional regulation by LXR. Knock-in of PPARgamma response elements can test their role in RCT.
Overexpression
CRISPR overexpression via CRISPRa or transgenic insertion can increase expression of RCT genes to test whether they overcome negative regulation. Overexpression of ABCG1 or PPARgamma can promote RCT and inhibit atherosclerosis. This approach helps identify rate-limiting steps in RCT.
How EDITGENE Supports negative regulation of reverse cholesterol transport Research
Researchers studying negative regulation of reverse cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in suppressing RCT or is merely a biomarker. CRISPR-based models provide a direct way to test causality by knocking out, mutating, or overexpressing specific genes in relevant cell types and animal models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of reverse cholesterol transport research.
Frequently Asked Questions About negative regulation of reverse cholesterol transport
What is GO:1903063 negative regulation of reverse cholesterol transport?
GO:1903063 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of reverse cholesterol transport.
What genes are involved in negative regulation of reverse cholesterol transport?
Key genes include LXR, PPARgamma, ABCA1, ABCG1, SR-BI, hepatic lipase, endothelial lipase, and signaling kinases ERK1/2.
How is reverse cholesterol transport negatively regulated?
It can be negatively regulated by inhibiting cholesterol efflux transporters, suppressing LXR or PPARgamma signaling, reducing HDL biogenesis, or blocking hepatic uptake and biliary excretion.
What diseases are linked to negative regulation of reverse cholesterol transport?
Atherosclerosis, obesity, and hepatic cholesterol accumulation are linked to reduced RCT.
Which signaling pathway suppresses reverse cholesterol transport?
The MEK/ERK pathway suppresses RCT, as MEK1/2 inhibitors activate macrophage ABCG1 and RCT.
How can I study negative regulation of reverse cholesterol transport in the lab?
In vivo RCT assays, cholesterol efflux assays, gene expression analysis, and CRISPR knockout models are commonly used.
What is the role of LXR in reverse cholesterol transport?
LXR transcriptionally activates ABCA1 and ABCG1; liver-specific LXR inhibition represses RCT in mice.
Does PPARgamma affect reverse cholesterol transport?
Yes, PPARgamma activation promotes RCT via the LXRalpha/beta-ABCA1 pathway and inhibits atherosclerosis.
What is the difference between RCT and negative regulation of RCT?
RCT is the forward process of cholesterol removal; negative regulation of RCT refers to processes that inhibit or reduce this removal.
Can CRISPR be used to study negative regulation of reverse cholesterol transport?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of specific genes in RCT.
Conclusion
GO:1903063 negative regulation of reverse cholesterol transport is a critical biological process that controls cholesterol homeostasis by suppressing the pathway that removes excess cholesterol from peripheral tissues to the liver. Its dysregulation contributes to atherosclerosis, obesity, and hepatic cholesterol accumulation. Key molecular players include LXR, PPARgamma, ABCA1, ABCG1, SR-BI, and signaling kinases such as ERK1/2. Researchers can leverage CRISPR-based models and functional assays to dissect the mechanisms of negative regulation and identify therapeutic targets. EDITGENE offers comprehensive services to support these studies, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Norum KR et al.. 1983. Transport of cholesterol.. Physiol Rev 63(4):1343-419 PMID: 6361811
- 2. Nishida T et al.. 2024. Liver-specific Lxr inhibition represses reverse cholesterol transport in cholesterol-fed mice.. Atherosclerosis 397:117578 PMID: 38797615
- 3. Xie J et al.. 2023. QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway.. J Ethnopharmacol 315:116684 PMID: 37230281
- 4. Annema W et al.. 2011. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport.. Curr Atheroscler Rep 13(3):257-65 PMID: 21424685
- 5. Jiménez-Cortegana C et al.. 2024. The Expression of Genes Related to Reverse Cholesterol Transport and Leptin Receptor Pathways in Peripheral Blood Mononuclear Cells Are Decreased in Morbid Obesity and Related to Liver Function.. Int J Mol Sci 25(14) PMID: 39062791
- 6. Zhang L et al.. 2016. MEK1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transport-An anti-atherogenic function of ERK1/2 inhibition.. Biochim Biophys Acta 1861(9 Pt A):1180-1191 PMID: 27365310
- 7. Pownall HJ et al.. 2019. Cholesterol: Can't Live With It, Can't Live Without It.. Methodist Debakey Cardiovasc J 15(1):9-15 PMID: 31049144
- 8. Jiang Q et al.. 2025. Integrated Multi-Omics Investigation of Gypenosides' Mechanisms in Lowering Hepatic Cholesterol.. Biomolecules 15(8) PMID: 40867648
